Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SPICE: A Robust Computational Framework for Identifying Copy Number Variations in Spatial Transcriptomics.

bioRxiv : the preprint server for biology·2026
Same author

A review of spontaneous bone metastases in domestic and laboratory animals.

Journal of bone oncology·2026
Same author

STDrug enables spatially informed personalized drug repurposing from spatial transcriptomics.

bioRxiv : the preprint server for biology·2026
Same author

Amoeboid-mesenchymal transition and the proteolytic control of cancer invasion plasticity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Amoeboid-Mesenchymal Transition and the Proteolytic Control of Cancer Invasion Plasticity.

bioRxiv : the preprint server for biology·2025
Same author

Pathology of a Canine Model of Localized Prostate Carcinoma.

The Prostate·2025

Related Experiment Video

Updated: Jul 16, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Why should we still care about oncogenes?

Kathleen M Diehl1, Evan T Keller, Kathleen M Woods Ignatoski

  • 1Department of Urology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0940, USA.

Molecular Cancer Therapeutics
|February 20, 2007
PubMed
Summary

Targeting oncogenes with small-molecule inhibitors, like Gleevec for chronic myelogenous leukemia, has revolutionized cancer treatment. Ongoing research addresses challenges such as drug resistance to improve patient outcomes.

More Related Videos

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Related Experiment Videos

Last Updated: Jul 16, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Oncogene mechanisms have been understood for decades, but targeting their protein function to inhibit cancer growth is a recent advancement.
  • Small-molecule inhibitors represent a significant breakthrough in cancer therapy, primarily targeting cellular oncogene counterparts.
  • Gleevec (imatinib) is a prime example of a molecular therapeutic agent.

Purpose of the Study:

  • To highlight the impact of small-molecule inhibitors in cancer treatment.
  • To compare the efficacy of traditional therapies with targeted molecular therapies.
  • To discuss the challenges and future directions in oncogene-targeted cancer therapy.

Main Methods:

  • Review of existing literature on oncogenes and small-molecule inhibitors.
  • Comparison of treatment outcomes for chronic myelogenous leukemia (CML) using IFN-alpha versus Gleevec.
  • Discussion of experimental studies addressing drug resistance mechanisms.

Main Results:

  • Gleevec targets the kinase activity of the proto-oncogene abl, significantly improving CML treatment.
  • Hematologic response rates in CML patients treated with Gleevec are 95%, with 89% progression-free survival at 18 months.
  • While drug resistance is a challenge, new therapies and combination treatments are being developed.

Conclusions:

  • Targeted molecular therapies, exemplified by Gleevec, have dramatically improved cancer treatment efficacy.
  • Further research is essential to overcome drug resistance and enhance long-term patient survival.
  • The development of novel drugs and combination strategies holds promise for future cancer therapy.